New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 7, 2013
18:59 EDTLNKD, ATVI, MCHP, UBTI, NUAN, CSTR, RVBD, SPWR, ETRMOn The Fly: After Hours Movers
UP AFTER EARNINGS: LinkedIn (LNKD), up 10%... Activision Blizzard (ATVI), up 5.4%... Microchip Technology (MCHP), up 6.5%... Ubiquiti Networks (UBTI), up 8.9%... DOWN AFTER EARNINGS: Nuance (NUAN), down 14.5%... Coinstar (CSTR), down 8.5%... Riverbed (RVBD), down 8.8%... SunPower (SPWR), 5%... ALSO LOWER: EnteroMedics (ETRM), down 51% after its ReCharge trial failed to meet an efficacy endpoint.
News For LNKD;ATVI;MCHP;UBTI;NUAN;CSTR;RVBD;SPWR;ETRM From The Last 14 Days
Check below for free stories on LNKD;ATVI;MCHP;UBTI;NUAN;CSTR;RVBD;SPWR;ETRM the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
August 29, 2014
11:21 EDTATVITake-Two could be Activision takeover target, says Benchmark Co.
Subscribe for More Information
11:07 EDTMCHPHigh option volume stocks
Subscribe for More Information
August 28, 2014
18:13 EDTMCHPOn The Fly: After Hours Movers
Subscribe for More Information
17:46 EDTMCHPMicrochip Technology confirms preliminary discussions with CSR plc
Microchip Technology Incorporated (MCHP) announced that it has had preliminary mutual discussions with CSR plc (CSRE) regarding ways in which its relationship with CSR could be advanced, including possibly an acquisition of CSR, a leading provider of AV, connectivity and location technology. Microchip and CSR have worked together on business initiatives in the past, such as a Bluetooth module initiative. The discussions between the parties are at a very preliminary stage and there can be no certainty that an offer will be made, nor as to the terms on which any offer might be made, or that any other type of transaction will be entered into with CSR or as to the terms, structure or form of any such transaction.
15:03 EDTMCHPCSR a potential target for TI, Broadcom after spurning Microchip, Bloomberg says
Subscribe for More Information
12:15 EDTLNKDLinkedIn management to meet with Piper Jaffray
Subscribe for More Information
11:44 EDTMCHPCSR surges after confirming rejection of Microchip takeover offer
Subscribe for More Information
08:55 EDTETRMOn The Fly: Pre-market Movers
HIGHER: Digital Ally (DGLY), up 16% after announcing order from Michigan State Police for over $1.1M... EnteroMedics (ETRM), up 12.4% after reporting three-year data from Maestro RC system... Repros (RPRX), up 0.8% after Androxal achieves superiority in both co-primary endpoints in a study... Synthetic Biologics (SYN), up 2.7% after Pfizer (PFE) was granted FDA Fast Track designation for its investigational Clostridium difficile vaccine candidate. Synthetic Biologics announced earlier this week that SYN-004, the company's lead anti-infective product candidate for the prevention of the effects of C. difficile, will be presented in October... Signet (SIG), up 3.9% after Q2 revenue tops consensus. DOWN AFTER EARNINGS: Abercrombie & Fitch (ANF), down 5.7%... Guess (GES), down 8.3%... Frontline (FRO), down 7%. ALSO LOWER: Williams-Sonoma (WSM), down 10.9% after downgraded at Morgan Stanley following the company's Q2 earnings report... GT Advanced (GTAT), down 2% after downgraded at Raymond James... Sungy Mobile (GOMO), down 20.1% following earnings report, CFO resignation, downgrade of stock at Oppenheimer... Genesco (GCO), down 7.7% after cutting fiscal year forecast.
07:09 EDTETRMEnteroMedics reports three-year data from Maestro RC system
EnteroMedics announced that three year diabetes, hypertension and weight loss data from the company's DM2 ENABLE Study of VBLOC vagal blocking therapy delivered via the Maestro Rechargeable System continue to demonstrate both medically meaningful weight loss as well as improvement in diabetes control in obese subjects with Type II Diabetes Mellitus. The DM2 Study is designed to evaluate the safety and efficacy of VBLOC vagal blocking therapy delivered via the Maestro RC System in 28 diabetic subjects with obesity by measuring average percentage excess weight loss, blood sugar, fasting plasma glucose and blood pressure, following device activation. To date, no unanticipated adverse device effects have been reported and the safety profile is similar to that seen in other VBLOC clinical trials. These metabolic effects in diabetes, hypertension and weight loss are consistent with previous findings from other time points and are considered medically meaningful improvements.
06:12 EDTMCHPCSR rejects offer from Microchip
Subscribe for More Information
August 26, 2014
11:48 EDTLNKDLinkedIn management to meet with Piper Jaffray
Subscribe for More Information
09:51 EDTLNKDOn The Fly: Analyst Initiation Summary
Cray (CRAY) initiated with a Buy at Stifel... Enphase Energy (ENPH) initiated with a Buy at Needham... FCB Financial (FCB) initiated with a Buy at UBS... FCB Financial initiated with an Overweight at JPMorgan... Goldman Sachs (GS) initiated with a Buy at MKM Partners... HealthEquity (HQY) initiated with a Neutral at RW Bair... Mobileye (MBLY) initiated with a Buy at Deutsche Bank... Mobileye initiated with a Neutral at Goldman... Mobileye initiated with a Neutral at RW Baird... Mobileye initiated with an Overweight at Barclays... RAIT Financial (RAS) initiated with an Outperform at JMP Securities... SunEdison (SUNE) initiated with an Outperform at FBR Capital... Mobileye initiated with an Outperform at Raymond James... Transocean Partners (RIG) initiated with an Overweight at Morgan Stanley... GT Advanced (GTAT) coverage resumed with an Overweight at Piper Jaffray... LinkedIn (LNKD) initiated with an Overweight at First Analysis... CSC (CSC) initiated with a Sector Perform at RBC Capital... United Natural Foods (UNFI) initiated with an Overweight at Stephens.
07:03 EDTLNKDLinkedIn initiated with an Overweight at First Analysis
Target $280.
August 22, 2014
11:59 EDTATVIGameStop surges after Q2 EPS, revenue beat expectations
Subscribe for More Information
August 21, 2014
16:46 EDTLNKDLinkedIn product head to leave company, effective October 3
Subscribe for More Information
August 20, 2014
08:42 EDTATVIActivision Blizzard price target raised to $30 from $24 at Argus
Subscribe for More Information
08:01 EDTLNKDAd spending on LinkedIn reportedly rising, says Pacific Crest
Subscribe for More Information
August 19, 2014
10:32 EDTLNKDRumor: LinkedIn moves lower on speculation of a large investor short position
August 18, 2014
17:00 EDTNUANNuance amends stockholders rights plan
Subscribe for More Information
16:02 EDTRVBDRiverbed names Paul Mountford as Chief Sales Officer
Riverbed Technology announced that Paul Mountford has joined the company as senior vice president and Chief Sales Officer. He was most recently CEO of Sentillian, a New York-based web intelligence startup.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use